Reata Pharmaceuticals Inc expected to post a loss of $2.88 a share - Earnings Preview

Reata Pharmaceuticals

04/08/2023 17:19

* Reata Pharmaceuticals Inc  RETA.OQ   RETA.O  is expected
to show
a fall in quarterly revenue when it reports  results on August 7
(estimated). 
    * The Plano Texas-based  company is expected to report  a
84.4% decrease in revenue to $118.5 thousand from $762 thousand
a year ago, according to the mean estimate from 8 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Reata
Pharmaceuticals Inc
is for a loss of $2.88 per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 10
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Reata
Pharmaceuticals Inc is $172.5​, above​ its last closing price
of $167.16. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -2.43       -2.42      -3.14     Missed  -29.7
 Dec. 31 2023  -2.23       -2.21      -2.33     Missed  -5.4
 Sep. 30 2022  -2.14       -2.18      -2.16     Beat    1​
 Jun. 30 2022  -2.03       -2.02      -2.02     Met     0.1
 ​​Mar.        -2.17       -2.17      -2.03     Beat    6.5
 31 2022                                                
 Dec. 31 2021  -2.30       -2.31      -2.35     Missed  -1.8​
 Sep. 30 2021  -2.16       -2.16      -1.97     Beat    9
 Jun. 30 2021  -2.02       -2.06      -2.00     Beat    2.8
 This summary was machine generated August 4 at 16:19 GMT.  All
figures in US dollars  unless otherwise stated